Effect on coronary flow velocity reserve in patients with type 2 diabetes mellitus: Comparison between angiotensin-converting enzyme inhibitor and angiotensin II type 1 receptor antagonist

American Heart Journal

Volumn 151, Issue 4, 2006, Pages 798.e9-798.e15

  Kawata, Takayuki ^a   Daimon, Masao ^a   Hasegawa, Rei ^a   Teramoto, Kiyomi ^a   Toyoda, Tomohiko ^a   Sekine, Tai ^a   Yamamoto, Kyohei ^b   Uchida, Daigaku ^b   Himi, Toshiharu ^b   Yoshida, Katsuya ^a   Komuro, Issei ^a  

^a CHIBA UNIVERSITY   (Japan)

^b KIMITSU CHUO HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; TEMOCAPRIL;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; DOPPLER ECHOCARDIOGRAPHY; FEMALE; FLOW RATE; HEART HEMODYNAMICS; HEART LEFT VENTRICLE MASS; HUMAN; HYPEREMIA; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; TRANSTHORACIC ECHOCARDIOGRAPHY;

EID: 33645244121     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2005.09.014     Document Type: Article

References (32)

1. H. King, R.E. Aubert, and W.H. Herman Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections Diabetes Care 21 1998 1414 1431
2. T.C. Fagan, and J. Sowers Type 2 diabetes mellitus: greater cardiovascular risks and greater benefits of therapy Arch Intern Med 159 1999 1033 1034
3. S.M. Factor, B.H. Segal, and K.H. van Hoeven Diabetes and coronary artery disease Coron Artery Dis 3 1992 4 10
4. J.N. Cohn, G. Tognoni, and Valsartan Heart Failure Trial Investigators A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure N Engl J Med 345 2001 1667 1675
5. The SOLVD Investigators Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure N Engl J Med 325 1991 293 302
6. B. Dahlof, R.B. Devereux, and S.E. Kjeldsen Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol Lancet 359 2002 995 1003
7. S. Yusuf, P. Sleight, and J. Pogue Effects of an angiotensin-converting- enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators N Engl J Med 342 2000 145 153
8. J.R. Sowers Treatment of hypertension in patients with diabetes Arch Intern Med 164 2004 1850 1857
9. Heart Outcomes Prevention Evaluation Study Investigators Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy Lancet 355 2000 253 259
10. B.M. Brenner, M.E. Cooper, and D. de Zeeuw Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy N Engl J Med 345 2001 861 869
11. E.J. Lewis, L.G. Hunsicker, and W.R. Clarke Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes N Engl J Med 345 2001 851 860
12. O.O. Akinboboye, R.L. Chou, and S.R. Bergmann Augmentation of myocardial blood flow in hypertensive heart disease by angiotensin antagonists: a comparison of lisinopril and losartan J Am Coll Cardiol 40 2002 703 709
13. A. Kjaer, C. Meyer, and F.S. Nielsen Dipyridamole, cold pressor test, and demonstration of endothelial dysfunction: a PET study of myocardial perfusion in diabetes J Nucl Med 44 2003 19 23
14. K.L. Gould Coronary artery stenosis and reversing atherosclerosis 2nd ed. 1999 Arnold Publishing New York
15. I. Yokoyama, S. Momomura, and T. Ohtake Reduced myocardial flow reserve in non-insulin-dependent diabetes mellitus J Am Coll Cardiol 30 1997 1472 1477
16. A. Nitenberg, P. Valensi, and R. Sachs Impairment of coronary vascular reserve and ACh-induced coronary vasodilation in diabetic patients with angiographically normal coronary arteries and normal left ventricular systolic function Diabetes 42 1993 1017 1025
17. T. Hozumi, K. Yoshida, and T. Akasaka Noninvasive assessment of coronary flow velocity and coronary flow velocity reserve in the left anterior descending coronary artery by Doppler echocardiography: comparison with invasive technique J Am Coll Cardiol 32 1998 1251 1259
18. T. Hozumi, K. Yoshida, and Y. Ogata Noninvasive assessment of significant left anterior descending coronary artery stenosis by coronary flow velocity reserve with transthoracic color Doppler echocardiography Circulation 97 1998 1557 1562
19. M. Daimon, H. Watanabe, and H. Yamagishi Physiologic assessment of coronary artery stenosis by coronary flow reserve measurements with transthoracic Doppler echocardiography: comparison with exercise thallium-201 single-photon emission computed tomography J Am Coll Cardiol 37 2001 1310 1315
20. R.B. Devereux, and N. Reichek Echocardiographic determination of left ventricular mass in man: anatomic validation of the method Circulation 55 1977 613 618
21. Z.Y. Fang, J.B. Prins, and T.H. Marwick Diabetic cardiomyopathy: evidence, mechanisms, and therapeutic implications Endocr Rev 25 2004 543 567
22. L.A. Nikolaidis, A. Doverspike, and R. Huerbin Angiotensin-converting enzyme inhibitors improve coronary flow reserve in dilated cardiomyopathy by a bradykinin-mediated, nitric oxide-dependent mechanism Circulation 105 2002 2785 2790
23. T. Kuga, M. Mohri, and K. Egashira Bradykinin-induced vasodilation of human coronary arteries in vivo: role of nitric oxide and angiotensin-converting enzyme J Am Coll Cardiol 30 1997 108 112
24. P. Gohlke, I. Kuwer, and A. Schnell Blockade of bradykinin B2 receptors prevents the increase in capillary density induced by chronic angiotensin-converting enzyme inhibitor treatment in stroke-prone spontaneously hypertensive rats Hypertension 29 1997 478 482
25. P. Smith, S.B. Williams, and D.E. Lipson Endothelial release of nitric oxide contributes to the vasodilator effect of adenosine in humans Circulation 92 1995 2135 2141
26. N.H. Buus, M. Bottcher, and F. Hermansen Influence of nitric oxide synthase and adrenergic inhibition of adenosine-induced myocardial hyperemia Circulation 104 2001 2305 2310
27. J. Zanzinger, and E. Bassenge Coronary vasodilation to acetylcholine, adenosine and bradykinin in dogs: effects of inhibition of NO-synthesis and captopril Eur Heart J 14 Suppl I 1993 164 168
28. H.S. Lim, R.J. MacFadyen, and G.Y. Lip Diabetes mellitus, the renin-angiotensin-aldosterone system, and the heart Arch Intern Med 164 2004 1737 1748
29. J.I.E. Hoffman A critical review of coronary reserve Circulation 75 Suppl I 1987 I-6 I-11
30. R.F. Wilson, D.E. Laughlin, and P.H. Ackell Transluminal subselective measurement of coronary artery blood flow velocity and vasodilator reserve in man Circulation 72 1985 82 92
31. D.D. Miller, T.J. Donohue, and T.L. Wolford Assessment of blood flow distal to coronary artery stenoses: correlations between myocardial positron emission tomography and poststenotic intracoronary Doppler flow reserve Circulation 94 1996 2447 2454
32. Y. Matsumura, T. Hozumi, and H. Watanabe Cut-off value of coronary flow velocity reserve by transthoracic Doppler echocardiography for diagnosis of significant left anterior descending artery stenosis in patients with coronary risk factors Am J Cardiol 92 2003 1389 1393